biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Stagliano's Neuron23 Raises Another $100 million

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Mar 30, 2022 8:15pm

107 Views

Post# 34561111

RE:RE:RE:RE:RE:RE:Stagliano's Neuron23 Raises Another $100 million

Yes. Continue, beenthere. Which management?

Look, the 10 years, 14 actually, are owned by the oldest management, not the current one.

That amount of time has done us damage. No question.

It's also allowed some very formidable technologies to advance.

That's one of the most important points of my earlier Neuron23 post.

It's no problem for me to write a very negative story about Bioasis. It would start with 25¢.

It's also no problem to write a very positive story about Bioasis.

I think I'll try to write both. They're both valid.

jd

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China